Posted 8th January 2018 by Laura Berry
Antibody-drug conjugates (ADCs) combine the high specificity of a monoclonal antibody (mAb) for a target antigen with the highly potent cytotoxic activity of small-molecule drugs. Although the concept behind ADCs is relatively simple, the successful design and development of ADCs is a complex task. Similar to other biotherapeutics, the understanding of Pharmacokinetics (PK), Pharmacodynamics (PD), and Absorption, Distribution, Metabolism, and Excretion (ADME) properties of ADCs is critical for their successful development.
Posted 9th October 2017 by Jane Williams
Presented at the 3rd Biologics and Biosimilars Congress, these 3 sets of slides are available to download and share with your colleagues.
Posted 13th September 2017 by Laura Berry
In this 30 minute presentation, Ralf Schumacher discusses developing and manufacturing biologics. Translating discovery knowledge into process design, technology upgrading and gated development paradigms are explored.
Posted 27th January 2017 by Jane Williams
Assays are crucial during pre-clinical and clinical trials, and for pharmacovigilance. By this stage, the molecule has already been fully profiled with a mechanism of action, and efficacy and safety are now being assessed in vivo.
Posted 16th January 2017 by Jane Williams
The quality, accuracy and reliability of assays is particularly critical when developing biologics and biosimilars. Assays for biologics are more complicated than for small molecules, often relying on assays which provide relative measures in contrast to the more absolute measurements gained from standard crystallisation or purity profiles.
Posted 23rd December 2016 by Jane Williams
My research activity focuses on the exploration of new drug delivery technology (categorised into polymer complex/conjugates, nanomedicine, and various types of drug delivery formulations) and the application of validated drug delivery technology to NCE candidates in early/exploratory research stages.